Relay Therapeutics Revenue and Competitors

Boston, MA USA

Location

$520M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Relay Therapeutics's estimated annual revenue is currently $47.3M per year.(i)
  • Relay Therapeutics received $400.0M in venture funding in December 2018.
  • Relay Therapeutics's estimated revenue per employee is $134,304
  • Relay Therapeutics's total funding is $520M.

Employee Data

  • Relay Therapeutics has 352 Employees.(i)
  • Relay Therapeutics grew their employee count by 5% last year.

Relay Therapeutics's People

NameTitleEmail/Phone
1
Principal Sci -> VP at Relay TherapeuticsReveal Email/Phone
2
VP Computational ArchitectureReveal Email/Phone
3
VP, Medical AffairsReveal Email/Phone
4
ControllerReveal Email/Phone
5
VP, Head Regulatory AffairsReveal Email/Phone
6
VP, Head Biometrics and Clinical Data ManagementReveal Email/Phone
7
VP, Clinical Business Operations and InnovationReveal Email/Phone
8
VP Machine LearningReveal Email/Phone
9
VP, Clinical DevelopmentReveal Email/Phone
10
VP, New Product PlanningReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Relay Therapeutics?

Relay Therapeutics is building the world's first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. By placing protein motion at the heart of drug discovery, Relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. Headquartered in Cambridge, Mass., Relay Therapeutics is a private company launched in 2016. To date, Relay Therapeutics has raised $120M in financing from Third Rock Ventures, BVF Partners, GV (formerly Google Ventures), an affiliate of D.E. Shaw Research, Casdin Capital, EcoR1 Capital, Section 32 and Alexandria Venture Investments. Our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. If you're creative, collaborative and passionate about making a difference in the lives of patients, join us!

keywords:Biotechnology,Healthcare,Pharmaceuticals

$520M

Total Funding

352

Number of Employees

$47.3M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Relay Therapeutics News

2022-04-17 - Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average ...

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an...

2022-04-17 - Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells ...

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an...

2022-04-13 - Relay Therapeutics Scores Relative Strength Rating Upgrade ...

Relay Therapeutics holds the No. 80 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharmaceutcls (AMPH) and...

2021-10-08 - Relay Therapeutics : Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα - Form 8-K

Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα RLY-2608 preferentially binds mutant PI3Kα at a novel allosteric site discovered by the Dynamo™ platform Preclinically, achieved tumor regressions in vivo w ...

2021-04-16 - RELAY THERAPEUTICS, INC. Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines by Acquiring ZebiAI

Relay Therapeutics’ leadership in this new breed of biotech positions the company as a strategic partner of choice for emerging technologies and founders in these fields ZebiAI amplifies Relay Therapeutics’ Dynamo™ platform with a library of industry-leading experimental DEL data sets and valid ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$109.5M356-46%N/A
#2
$65.4M361N/AN/A
#3
$63.4M3627%N/A
#4
$65.6M362N/AN/A
#5
$1.8M367-4%$538M

Relay Therapeutics Funding

DateAmountRoundLead InvestorsReference
2016-09-15$57.0MAThird Rock Ventures, LLCArticle
2017-12-15$63.0MBBVF PartnersArticle
2018-12-21$400.0MCSoftBank Vision FundArticle